Загрузка...
TP53-Mutated Circulating Tumor DNA for Disease Monitoring in Lymphoma Patients after CAR T Cell Therapy
Chimeric antigen receptor T (CAR T) cell immunotherapy has shown remarkable efficacy in non-Hodgkin’s lymphoma (NHL) patients. Minimal residual disease (MRD) monitoring in NHL is essential after CAR T cell therapy, which can be achieved by monitoring circulating tumor DNA (ctDNA). The mutation of TP...
Сохранить в:
| Опубликовано в: : | Diagnostics (Basel) |
|---|---|
| Главные авторы: | , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8151854/ https://ncbi.nlm.nih.gov/pubmed/34066756 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics11050844 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|